Recent developments in esophageal adenocarcinoma

CA Cancer Journal for Clinicians

Volumn 63, Issue 4, 2013, Pages 232-248

  Lagergren, Jesper ^a,b   Lagergren, Pernilla ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Barrett esophagus; esophagus; health related quality of life; incidence; neoplasm; patterns; prognosis; therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CELECOXIB; ESOMEPRAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTON PUMP INHIBITOR; SEX HORMONE; SIMVASTATIN;

ARTICLE; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER SURVIVAL; CAUSAL ATTRIBUTION; CHEMORADIOTHERAPY; CLINICAL PATHWAY; EARLY DIAGNOSIS; ENDOSCOPIC THERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS DYSPLASIA; ESOPHAGUS RESECTION; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; INTERMETHOD COMPARISON; LUNG COMPLICATION; OBESITY; PATHOGENESIS; PATIENT MONITORING; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SEX RATIO; SURGICAL APPROACH; SURVIVAL RATE; TREATMENT OUTCOME; WEIGHT REDUCTION;

BARRETT ESOPHAGUS; ESOPHAGUS; HEALTH-RELATED QUALITY OF LIFE; INCIDENCE; NEOPLASM; PATTERNS; PROGNOSIS; THERAPY;

ADENOCARCINOMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BARRETT ESOPHAGUS; BREAST FEEDING; COMBINED MODALITY THERAPY; CRITICAL PATHWAYS; DEGLUTITION DISORDERS; EARLY DETECTION OF CANCER; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; GASTROESOPHAGEAL REFLUX; GENES, ERBB-2; GENETIC PREDISPOSITION TO DISEASE; GONADAL STEROID HORMONES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; OBESITY; PALLIATIVE CARE; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PRIMARY PREVENTION; PROGNOSIS; PROTON PUMP INHIBITORS; QUALITY OF LIFE; RISK FACTORS; SEX DISTRIBUTION; STENTS; TUMOR MARKERS, BIOLOGICAL; WEIGHT LOSS;

EID: 84879752910     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21185     Document Type: Article

References (184)

1. Edgren G, Adami HO, Weiderpass E, Nyren O,. A global assessment of the oesophageal adenocarcinoma epidemic [published online ahead of print January 8, 2013]. Gut. doi: 10.1136/gutjnl-2012-302412.short.
2. Cook MB, Chow WH, Devesa SS,. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer. 2009; 101: 855-859.
3. Strong VE, D'Amico TA, Kleinberg L, Ajani J,. Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. J Natl Compr Canc Netw. 2013; 11: 60-66.
4. Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013; 119: 1149-1158.
5. Pohl H, Sirovich B, Welch HG,. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev. 2010; 19: 1468-1470.
6. Lagergren J, Mattsson F,. No further increase in the incidence of esophageal adenocarcinoma in Sweden. Int J Cancer. 2011; 129: 513-516.
7. Thrift AP, Whiteman DC,. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012; 23: 3155-3162.
8. Orloff M, Peterson C, He X, et al. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAMA. 2011; 306: 410-419.
9. Reid BJ, Li X, Galipeau PC, Vaughan TL,. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer. 2010; 10: 87-101.
10. Cheung WY, Zhai R, Bradbury P, et al. Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma. Int J Cancer. 2012; 131: 2478-2486.
11. McElholm AR, McKnight AJ, Patterson CC, Johnston BT, Hardie LJ, Murray LJ,; Finbar Group. A population-based study of IGF axis polymorphisms and the esophageal inflammation, metaplasia, adenocarcinoma sequence. Gastroenterology. 2010; 139: 204-212.e3.
12. Menke V, Pot RG, Moons LM, et al. Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett's esophagus and esophageal adenocarcinoma. J Hum Genet. 2012; 57: 26-32.
13. Zhai R, Liu G, Asomaning K, et al. Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis. 2008; 29: 2330-2334.
14. Babar M, Ryan AW, Anderson LA, et al. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma. Am J Gastroenterol. 2012; 107: 1331-1341.
15. Lagergren J, Bergstrom R, Lindgren A, Nyren O,. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999; 340: 825-831.
16. Rubenstein JH, Taylor JB,. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther. 2010; 32: 1222-1227.
17. Sharma P,. Clinical practice. Barrett's esophagus. N Engl J Med. 2009; 361: 2548-2556.
18. Zhai R, Chen F, Liu G, et al. Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol. 2010; 28: 2445-2451.
19. Doecke J, Zhao ZZ, Pandeya N, et al. Australian Cancer Study. Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma. Int J Cancer. 2008; 123: 174-180.
20. Ness-Jensen E, Lindam A, Lagergren J, Hveem K,. Changes in prevalence, incidence and spontaneous loss of gastro-oesophageal reflux symptoms: a prospective population-based cohort study, the HUNT study. Gut. 2012; 61: 1390-1397.
21. Hoyo C, Cook MB, Kamangar F, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol. 2012; 41: 1706-1718.
22. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M,. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371: 569-578.
23. Turati F, Tramacere I, La Vecchia C, Negri I,. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol. 2013; 24: 609-617.
24. Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL,. Central adiposity and risk of Barrett's esophagus. Gastroenterology. 2007; 133: 403-411.
25. Corley DA, Kubo A, Zhao W,. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev. 2008; 17: 352-358.
26. O'Doherty MG, Freedman ND, Hollenbeck AR, Schatzkin A, Abnet CC,. A prospective cohort study of obesity and risk of oesophageal and gastric adenocarcinoma in the NIH-AARP Diet and Health Study. Gut. 2012; 61: 1261-1268.
27. van Kruijsdijk RC, van der Wall E, Visseren FL,. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2569-2578.
28. Ryan AM, Healy LA, Power DG, et al. Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann Surg. 2008; 247: 909-915.
29. Doyle SL, Donohoe CL, Finn SP, et al. IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity. Am J Gastroenterol. 2012; 107: 196-204.
30. Donohoe CL, Doyle SL, McGarrigle S, et al. Role of the insulin-like growth factor 1 axis and visceral adiposity in oesophageal adenocarcinoma. Br J Surg. 2012; 99: 387-396.
31. Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J,. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA. 2003; 290: 66-72.
32. Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA Jr,. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006; 354: 2340-2348.
33. Dent J, Becher A, Sung J, Zou D, Agreus L, Bazzoli F,. Systematic review: patterns of reflux-induced symptoms and esophageal endoscopic findings in large-scale surveys. Clin Gastroenterol Hepatol. 2012; 10: 863-873.e3.
34. Kong CY, Nattinger KJ, Hayeck TJ, et al. The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model. Cancer Epidemiol Biomarkers Prev. 2011; 20: 2450-2456.
35. Conteduca V, Sansonno D, Lauletta G, Russi S, Ingravallo G, Dammacco F,. H. pylori infection and gastric cancer: state of the art (review). Int J Oncol. 2013; 42: 5-18.
36. Whiteman DC, Parmar P, Fahey P, et al. Australian Cancer Study. Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology. 2010; 139: 73-83; quiz e11-e12.
37. Anderson LA, Murphy SJ, Johnston BT, et al. Relationship between Helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: results from the FINBAR case-control study. Gut. 2008; 57: 734-739.
38. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G,. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol. 2007; 5: 1413-1417, 1417.e1-2.
39. Islami F, Sheikhattari P, Ren JS, Kamangar F,. Gastric atrophy and risk of oesophageal cancer and gastric cardia adenocarcinoma-a systematic review and meta-analysis. Ann Oncol. 2011; 22: 754-760.
40. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012; 13: 607-615.
41. Goh KL, Chan WK, Shiota S, Yamaoka Y,. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter. 2011; 16 (suppl 1): 1-9.
42. Peleteiro B, La Vecchia C, Lunet N,. The role of Helicobacter pylori infection in the web of gastric cancer causation. Eur J Cancer Prev. 2012; 21: 118-125.
43. Nyren O, Blot WJ,. Helicobacter pylori infection: mainly foe but also friend? J Natl Cancer Inst. 2006; 98: 1432-1434.
44. Lubin JH, Cook MB, Pandeya N, et al. The importance of exposure rate on odds ratios by cigarette smoking and alcohol consumption for esophageal adenocarcinoma and squamous cell carcinoma in the Barrett's Esophagus and Esophageal Adenocarcinoma Consortium. Cancer Epidemiol. 2012; 36: 306-316.
45. Cook MB, Kamangar F, Whiteman DC, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst. 2010; 102: 1344-1353.
46. van Meijgaard J, Fielding JE,. Estimating benefits of past, current, and future reductions in smoking rates using a comprehensive model with competing causes of death. Prev Chronic Dis. 2012; 9: E122.
47. Pandeya N, Webb PM, Sadeghi S, Green AC, Whiteman DC,; Australian Cancer Study. Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants? Gut. 2010; 59: 31-38.
48. Freedman ND, Murray LJ, Kamangar F, et al. Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut. 2011; 60: 1029-1037.
49. Pandeya N, Williams G, Green AC, Webb PM, Whiteman DC,; Australian Cancer Study. Alcohol consumption and the risks of adenocarcinoma and squamous cell carcinoma of the esophagus. Gastroenterology. 2009; 136: 1215-1224, e1-e2.
50. Anderson LA, Cantwell MM, Watson RG, et al. The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Gastroenterology. 2009; 136: 799-805.
51. Kubo A, Corley DA, Jensen CD, Kaur R,. Dietary factors and the risks of oesophageal adenocarcinoma and Barrett's oesophagus. Nutr Res Rev. 2010; 23: 230-246.
52. Huang W, Han Y, Xu J, Zhu W, Li Z,. Red and processed meat intake and risk of esophageal adenocarcinoma: a meta-analysis of observational studies. Cancer Causes Control. 2013; 24: 193-201.
53. Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003; 95: 1404-1413.
54. Olsen CM, Pandeya N, Green AC, Webb PM, Whiteman DC,; Australian Cancer Study. Population attributable fractions of adenocarcinoma of the esophagus and gastroesophageal junction. Am J Epidemiol. 2011; 174: 582-590.
55. Huang W, Ren H, Ben Q, Cai Q, Zhu W, Li Z,. Risk of esophageal cancer in diabetes mellitus: a meta-analysis of observational studies. Cancer Causes Control. 2012; 23: 263-272.
56. Persson EC, Shiels MS, Dawsey SM, Bhatia K, Anderson LA, Engels EA,. Increased risk of stomach and esophageal malignancies in people with AIDS. Gastroenterology. 2012; 143: 943-950.e2.
57. Rutegard M, Nordenstedt H, Lu Y, Lagergren J, Lagergren P,. Sex-specific exposure prevalence of established risk factors for oesophageal adenocarcinoma. Br J Cancer. 2010; 103: 735-740.
58. Erichsen R, Robertson D, Farkas DK, et al. Erosive reflux disease increases risk for esophageal adenocarcinoma, compared with nonerosive reflux. Clin Gastroenterol Hepatol. 2012; 10: 475-480.e1.
59. Lagergren K, Mattsson F, Lagergren J,. Abdominal adiposity might not contribute to the male predominance in esophageal adenocarcinoma. Epidemiology. In press.
60. Lofdahl HE, Lu Y, Lagergren J,. Sex-specific risk factor profile in oesophageal adenocarcinoma. Br J Cancer. 2008; 99: 1506-1510.
61. Derakhshan MH, Liptrot S, Paul J, Brown IL, Morrison D, McColl KE,. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut. 2009; 58: 16-23.
62. Rutegard M, Shore R, Lu Y, Lagergren P, Lindblad M,. Sex differences in the incidence of gastrointestinal adenocarcinoma in Sweden 1970-2006. Eur J Cancer. 2010; 46: 1093-1100.
63. Sukocheva OA, Wee C, Ansar A, Hussey DJ, Watson DI,. Effect of estrogen on growth and apoptosis in esophageal adenocarcinoma cells [published online ahead of print November 16, 2012]. Dis Esophagus. doi: 10.1111/dote.12000.
64. Chandanos E, Lagergren J,. The mystery of male dominance in oesophageal cancer and the potential protective role of oestrogen. Eur J Cancer. 2009; 45: 3149-3155.
65. Lu Y, Lagergren J,. Reproductive factors and risk of oesophageal cancer, a population-based nested case-control study in Sweden. Br J Cancer. 2012; 107: 564-569.
66. Cronin-Fenton DP, Murray LJ, Whiteman DC, et al. Barrett's Esophagus, Adenocarcinoma Consortium (BEACON) Investigators. Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis. Eur J Cancer. 2010; 46: 2067-2076.
67. Kahrilas PJ,. Clinical practice. Gastroesophageal reflux disease. N Engl J Med. 2008; 359: 1700-1707.
68. Chang EY, Morris CD, Seltman AK, et al. The effect of antireflux surgery on esophageal carcinogenesis in patients with barrett esophagus: a systematic review. Ann Surg. 2007; 246: 11-21.
69. Garcia Rodriguez LA, Lagergren J, Lindblad M,. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut. 2006; 55: 1538-1544.
70. Nguyen DM, El-Serag HB, Henderson L, Stein D, Bhattacharyya A, Sampliner RE,. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2009; 7: 1299-1304.
71. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001; 285: 2331-2338.
72. Rees JR, Lao-Sirieix P, Wong A, Fitzgerald RC,. Treatment for Barrett's oesophagus. Cochrane Database Syst Rev. 2010 (1): CD004060.
73. Nguyen DM, Richardson P, El-Serag HB,. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology. 2010; 138: 2260-2266.
74. Kastelein F, Spaander MC, Steyerberg EW, et al. ProBar Study Group. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus [published online ahead of print November 28, 2012]. Clin Gastroenterol Hepatol. doi:pii: S1542-3565(12)01411-5. 10.1016/j.cgh. 2012.11.014.
75. Miyashita T, Shah FA, Harmon JW, et al. Do proton pump inhibitors protect against cancer progression in GERD? [published online ahead of print October 31, 2012] Surg Today.
76. Lagergren J, Ye W, Lagergren P, Lu Y,. The risk of esophageal adenocarcinoma after antireflux surgery. Gastroenterology. 2010; 138: 1297-1301.
77. Kauttu TM, Rantanen TK, Sihvo EI, Rasanen JV, Puolakkainen P, Salo JA,. Esophageal adenocarcinoma arising after antireflux surgery: a population-based analysis. Eur J Cardiothorac Surg. 2011; 40: 1450-1454; discussion 1454.
78. Lofdahl HE, Lu Y, Lagergren P, Lagergren J,. Risk factors for esophageal adenocarcinoma after antireflux surgery. Ann Surg. 2013; 257: 579-582.
79. Scozzari G, Trapani R, Toppino M, Morino M,. Esophagogastric cancer after bariatric surgery: systematic review of the literature. Surg Obes Relat Dis. 2013; 9: 133-142.
80. Bazuro GE, Torino F, Gasparini G, Capurso L,. Chemoprevention in gastrointestinal adenocarcinoma: for few but not for all? Minerva Gastroenterol Dietol. 2008; 54: 429-444.
81. Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A,. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer. 2009; 100: 551-557.
82. Liao LM, Vaughan TL, Corley DA, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology. 2012; 142: 442-452.e5; quiz e22-e23.
83. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C,. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012; 23: 1403-1415.
84. Lindblad M, Lagergren J, Garcia Rodriguez LA,. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14: 444-450.
85. Anderson LA, Johnston BT, Watson RG, et al. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia- adenocarcinoma sequence. Cancer Res. 2006; 66: 4975-4982.
86. Heath EI, Canto MI, Piantadosi S, et al. Chemoprevention for Barrett's Esophagus Trial Research Group. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007; 99: 545-557.
87. Falk GW, Buttar NS, Foster NR, et al. Cancer Prevention Network. A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology. 2012; 143: 917-926.e1.
88. Kastelein F, Spaander MC, Biermann K, Steyerberg EW, Kuipers EJ, Bruno MJ,; Probar-study Group. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology. 2011; 141: 2000-2008; quiz e13-e14.
89. Beales IL, Vardi I, Dearman L, Broughton T,. Statin use is associated with a reduction in the incidence of esophageal adenocarcinoma: a case control study [published online ahead of print September 18, 2012]. Dis Esophagus. doi: 10.1111/j.1442-2050.2012.01412.x.
90. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology. 2005; 129: 1825-1831.
91. Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008; 57: 1354-1349.
92. Lao-Sirieix P, Fitzgerald RC,. Screening for oesophageal cancer. Nat Rev Clin Oncol. 2012; 9: 278-287.
93. Gupta N, Gaddam S, Wani SB, Bansal A, Rastogi A, Sharma P,. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett's esophagus. Gastrointest Endosc. 2012; 76: 531-538.
94. Benaglia T, Sharples LD, Fitzgerald RC, Lyratzopoulos G,. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. Gastroenterology 2013; 144: 62-73.e6.
95. Rubenstein JH, Sonnenberg A, Davis J, McMahon L, Inadomi JM,. Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointest Endosc. 2008; 68: 849-855.
96. Shaheen NJ, Weinberg DS, Denberg TD, Chou R, Qaseem A, Shekelle P,; Clinical Guidelines Committee of the American College of Physicians. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Intern Med. 2012; 157: 808-816.
97. Thrift AP, Kendall BJ, Pandeya N, Whiteman DC,. A model to determine absolute risk for esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2013; 11: 138-144.e2.
98. Su Z, Gay LJ, Strange A, et al. Esophageal Adenocarcinoma Genetics Consortium; Wellcome Trust Case Control Consortium 2. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet. 2012; 44: 1131-1136.
99. Yang S, Wu S, Huang Y, et al. Screening for oesophageal cancer. Cochrane Database Syst Rev. 2012; 12: CD007883.
100. de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ,. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut. 2010; 59: 1030-1036.
101. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P,. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med. 2011; 365: 1375-1383.
102. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011; 103: 1049-1057.
103. Prasad GA, Bansal A, Sharma P, Wang KK,. Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol. 2010; 105: 1490-1502.
104. Bird-Lieberman EL, Neves AA, Lao-Sirieix P, et al. Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. Nat Med. 2012; 18: 315-321.
105. Bird-Lieberman EL, Dunn JM, Coleman HG, et al. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. Gastroenterology. 2012; 143: 927-935.e3.
106. Alvi MA, Liu X, O'Donovan M, et al. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus. Clin Cancer Res. 2013; 19: 878-888.
107. Revilla-Nuin B, Parrilla P, Lozano J, et al. Predictive value of microRNAs in the progression of Barrett esophagus to adenocarcinoma in a long-term follow-up study [published online ahead of print October 10, 2012]. Ann Surg.
108. Kastelein F, Biermann K, Steyerberg EW, et al. on behalf of the ProBar-study group. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus [published online ahead of print December 20, 2012]. Gut.
109. Wong R, Walker-Dilks C, Raifu A,. Evidence-based guideline recommendations on the use of positron emission tomography imaging in oesophageal cancer. Clin Oncol (R Coll Radiol). 2012; 24: 86-104.
110. Coupland VH, Lagergren J, Luchtenborg M, et al. Hospital volume, proportion resected and mortality from oesophageal and gastric cancer: a population-based study in England, 2004-2008 [published online ahead of print October 19, 2012]. Gut.
111. Rutegard M, Charonis K, Lu Y, Lagergren P, Lagergren J, Rouvelas I,. Population-based esophageal cancer survival after resection without neoadjuvant therapy: an update. Surgery. 2012; 152: 903-910.
112. Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, Lagergren J,. Survival after surgery for oesophageal cancer: a population-based study. Lancet Oncol. 2005; 6: 864-870.
113. Sjoquist KM, Burmeister BH, Smithers BM, et al. Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011; 12: 681-692.
114. Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R,; Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, the British Society of Gastroenterology and the British Association of Surgical Oncology. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011; 60: 1449-1472.
115. Lagarde SM, Vrouenraets BC, Stassen LP, van Lanschot JJ,. Evidence-based surgical treatment of esophageal cancer: overview of high-quality studies. Ann Thorac Surg. 2010; 89: 1319-1326.
116. Mariette C, Piessen G, Briez N, Gronnier C, Triboulet JP,. Oesophagogastric junction adenocarcinoma: which therapeutic approach? Lancet Oncol. 2011; 12: 296-305.
117. Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007; 246: 992-1000; discussion 1000-1001.
118. Gemmill EH, McCulloch P,. Systematic review of minimally invasive resection for gastro-oesophageal cancer. Br J Surg. 2007; 94: 1461-1467.
119. Galvani CA, Gorodner MV, Moser F, et al. Robotically assisted laparoscopic transhiatal esophagectomy. Surg Endosc. 2008; 22: 188-195.
120. Nafteux P, Moons J, Coosemans W, et al. Minimally invasive oesophagectomy: a valuable alternative to open oesophagectomy for the treatment of early oesophageal and gastro-oesophageal junction carcinoma. Eur J Cardiothorac Surg. 2011; 40: 1455-1463; discussion 1463-1464.
121. Parameswaran R, Blazeby JM, Hughes R, Mitchell K, Berrisford RG, Wajed SA,. Health-related quality of life after minimally invasive oesophagectomy. Br J Surg. 2010; 97: 525-531.
122. Briez N, Piessen G, Torres F, Lebuffe G, Triboulet JP, Mariette C,. Effects of hybrid minimally invasive oesophagectomy on major postoperative pulmonary complications. Br J Surg. 2012; 99: 1547-1553.
123. Dantoc M, Cox MR, Eslick GD,. Evidence to support the use of minimally invasive esophagectomy for esophageal cancer: a meta-analysis. Arch Surg. 2012; 147: 768-776.
124. Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012; 379: 1887-1892.
125. Finks JF, Osborne NH, Birkmeyer JD,. Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med. 2011; 364: 2128-2137.
126. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL,. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003; 349: 2117-2127.
127. Ghaferi AA, Birkmeyer JD, Dimick JB,. Variation in hospital mortality associated with inpatient surgery. N Engl J Med. 2009; 361: 1368-1375.
128. Stitzenberg KB, Sigurdson ER, Egleston BL, Starkey RB, Meropol NJ,. Centralization of cancer surgery: implications for patient access to optimal care. J Clin Oncol. 2009; 27: 4671-4678.
129. Rutegard M, Lagergren J, Rouvelas I, Lagergren P,. Surgeon volume is a poor proxy for skill in esophageal cancer surgery. Ann Surg. 2009; 249: 256-261.
130. Derogar M, Sadr-Azodi O, Johar A, Lagergren P, Lagergren J,. Hospital and surgeon volume in relation to survival after esophageal cancer surgery in a population-based study. J Clin Oncol. 2013; 31: 551-557.
131. van de Poll-Franse LV, Lemmens VE, Roukema JA, Coebergh JW, Nieuwenhuijzen GA,. Impact of concentration of oesophageal and gastric cardia cancer surgery on long-term population-based survival. Br J Surg. 2011; 98: 956-963.
132. Djarv T, Lagergren J, Blazeby JM, Lagergren P,. Long-term health-related quality of life following surgery for oesophageal cancer. Br J Surg. 2008; 95: 1121-1126.
133. Scarpa M, Valente S, Alfieri R, et al. Systematic review of health-related quality of life after esophagectomy for esophageal cancer. World J Gastroenterol. 2011; 17: 4660-4674.
134. Whistance RN, Blazeby JM,. Systematic review: quality of life after treatment for upper gastrointestinal cancer. Curr Opin Support Palliat Care. 2011; 5: 37-46.
135. Martin L, Lagergren P,. Long-term weight change after oesophageal cancer surgery. Br J Surg. 2009; 96: 1308-1314.
136. Derogar M, Lagergren P,. Health-related quality of life among 5-year survivors of esophageal cancer surgery: a prospective population-based study. J Clin Oncol. 2012; 30: 413-418.
137. Derogar M, Orsini N, Sadr-Azodi O, Lagergren P,. Influence of major postoperative complications on health-related quality of life among long-term survivors of esophageal cancer surgery. J Clin Oncol. 2012; 30: 1615-1619.
138. Djarv T, Blazeby JM, Lagergren P,. Predictors of postoperative quality of life after esophagectomy for cancer. J Clin Oncol. 2009; 27: 1963-1968.
139. Miller KR, Bozeman MC,. Nutrition therapy issues in esophageal cancer. Curr Gastroenterol Rep. 2012; 14: 356-366.
140. Ligthart-Melis GC, Weijs PJ, Te Boveldt ND, et al. Dietician-delivered intensive nutritional support is associated with a decrease in severe postoperative complications after surgery in patients with esophageal cancer [published online ahead of print December 13, 2012]. Dis Esophagus. doi: 10.1111/dote.12008.
141. Martin L, Lagergren J, Lindblad M, Rouvelas I, Lagergren P,. Malnutrition after oesophageal cancer surgery in Sweden. Br J Surg. 2007; 94: 1496-1500.
142. Martin L, Jia C, Rouvelas I, Lagergren P,. Risk factors for malnutrition after oesophageal and cardia cancer surgery. Br J Surg. 2008; 95: 1362-1368.
143. Martin L, Lagergren J, Jia C, Lindblad M, Rouvelas I, Viklund P,. The influence of needle catheter jejunostomy on weight development after oesophageal cancer surgery in a population-based study. Eur J Surg Oncol. 2007; 33: 713-717.
144. Kleinberg L, Forastiere AA,. Chemoradiation in the management of esophageal cancer. J Clin Oncol. 2007; 25: 4110-4117.
145. Cooper SL, Russo JK, Chin S,. Definitive chemoradiotherapy for esophageal carcinoma. Surg Clin North Am. 2012; 92: 1213-1248.
146. Prasad GA, Wu TT, Wigle DA, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology. 2009; 137: 815-823.
147. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009; 360: 2277-2288.
148. Dunbar KB, Spechler SJ,. The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett's esophagus: a systematic review. Am J Gastroenterol. 2012; 107: 850-862; quiz 863.
149. Konda VJ, Waxman I,. Endotherapy for Barrett's esophagus. Am J Gastroenterol. 2012; 107: 827-833.
150. Pech O, Bollschweiler E, Manner H, Leers J, Ell C, Hölscher AH,. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann Surg. 2011; 254: 67-72.
151. Leers JM, DeMeester SR, Oezcelik A, et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg. 2011; 253: 271-278.
152. Griffin SM, Burt AD, Jennings NA,. Lymph node metastasis in early esophageal adenocarcinoma. Ann Surg. 2011; 254: 731-736; discussion 736-737.
153. Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012; 143: 336-346.
154. Thosani N, Singh H, Kapadia A, et al. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. Gastrointest Endosc. 2012; 75: 242-253.
155. Hur C, Choi SE, Rubenstein JH, et al. The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology. 2012; 143: 567-575.
156. Orman ES, Kim HP, Bulsiewicz WJ, et al. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation. Am J Gastroenterol. 2013; 108: 187-195.
157. Thallinger CM, Raderer M, Hejna M,. Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol. 2011; 29: 4709-4714.
158. Hawkes E, Okines AF, Papamichael D, et al. Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. Eur J Cancer. 2011; 47: 1146-1151.
159. Bang YJ,. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J Clin Gastroenterol. 2012; 46: 637-648.
160. Sreedharan A, Harris K, Crellin A, Forman D, Everett SM,. Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst Rev. 2009;(4):C D005048.
161. Sgourakis G, Gockel I, Radtke A, et al. The use of self-expanding stents in esophageal and gastroesophageal junction cancer palliation: a meta-analysis and meta-regression analysis of outcomes. Dig Dis Sci. 2010; 55: 3018-3030.
162. Amdal CD, Jacobsen AB, Guren MG, Bjordal K,. Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review [published online ahead of print November 28, 2012]. Acta Oncol.
163. Bergquist H, Johnsson E, Nyman J, et al. Combined stent insertion and single high-dose brachytherapy in patients with advanced esophageal cancer-results of a prospective safety study. Dis Esophagus. 2012; 25: 410-415.
164. Blazeby JM, Wilson L, Metcalfe C, Nicklin J, English R, Donovan JL,. Analysis of clinical decision-making in multi-disciplinary cancer teams. Ann Oncol. 2006; 17: 457-460.
165. Stephens MR, Lewis WG, Brewster AE, et al. Multidisciplinary team management is associated with improved outcomes after surgery for esophageal cancer. Dis Esophagus. 2006; 19: 164-171.
166. Lagergren J, Lagergren P,. Oesophageal cancer. BMJ. 2010; 341: c6280.
167. Verschuur EM, Steyerberg EW, Tilanus HW, et al. Nurse-led follow-up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. Br J Cancer. 2009; 100: 70-76.
168. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-2917.
169. Lagergren J, Mattson F,. Diverging trends in recent population-based survival rates in oesophageal and gastric cancer. PLoS One. 2012; 7: e41352.
170. Cen P, Banki F, Cheng L, et al. Changes in age, stage distribution, and survival of patients with esophageal adenocarcinoma over three decades in the United States. Ann Surg Oncol. 2012; 19: 1685-1691.
171. Lagarde SM, ten Kate FJ, Reitsma JB, Busch OR, van Lanschot JJ,. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 2006; 24: 4347-4355.
172. Bohanes P, Yang D, Chhibar RS, et al. Influence of sex on the survival of patients with esophageal cancer. J Clin Oncol. 2012; 30: 2265-2272.
173. Yoon HH, Lewis MA, Shi Q, et al. Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. J Clin Oncol. 2011; 29: 4561-4567.
174. Rutegard M, Lagergren P, Rouvelas I, Mason R, Lagergren J,. Surgical complications and long-term survival after esophagectomy for cancer in a nationwide Swedish cohort study. Eur J Surg Oncol. 2012; 38: 555-561.
175. Djarv T, Metcalfe C, Avery KN, Lagergren P, Blazeby JM,. Prognostic value of changes in health-related quality of life scores during curative treatment for esophagogastric cancer. J Clin Oncol. 2010; 28: 1666-1670.
176. Djarv T, Lagergren P,. Six-month postoperative quality of life predicts long-term survival after oesophageal cancer surgery. Eur J Cancer. 2011; 47: 530-535.
177. Parameswaran R, McNair A, Avery KN, et al. The role of health-related quality of life outcomes in clinical decision making in surgery for esophageal cancer: a systematic review. Ann Surg Oncol. 2008; 15: 2372-2379.
178. Vallbohmer D, Brabender J, Metzger R, Holscher AH,. Genetics in the pathogenesis of esophageal cancer: possible predictive and prognostic factors. J Gastrointest Surg. 2010; 14 (suppl 1): S75-S80.
179. Cheung WY, Liu G,. Genetic variations in esophageal cancer risk and prognosis. Gastroenterol Clin North Am. 2009; 38: 75-91, viii.
180. Yoon HH, Shi Q, Sukov WR, et al. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol. 2012; 30: 3932-3938.
181. Peters CJ, Rees JR, Hardwick RH, et al. Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group. A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology. 2010; 139: 1995-2004.e15.
182. Baren JP, Stewart GD, Stokes A, et al. mRNA profiling of the cancer degradome in oesophago-gastric adenocarcinoma. Br J Cancer. 2012; 107: 143-149.
183. Goh XY, Rees JR, Paterson AL, et al. Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma. Gut. 2011; 60: 1317-1326.
184. 18F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol. 2010; 28: 4714-4721.